Geopolitical news is providing a lift to the auto rental sector.Shares of Avis Budget Group (CAR 20.42%) and Hertz Global Holdings (HTZ 23.62%) each traded up about 20% as of noon ET as investors bet new tariffs on imported vehicles will have a positive impact on their businesses.A complex modelA move by the White House to place 25% tariffs on imported vehicles is likely to create a range of winners and losers among automakers and related businesses. The impact, at least in the near term, is to add thousand ...

ALMERE, Netherlands, March 25, 2025 (GLOBE NEWSWIRE) -- The foundation of weight reduction therapy, which was discovered a century ago, is the utilization of the body's innate mechanism for energy production. Due to its propensity to produce quick and long-lasting weight loss, a weight-loss diet has become a popular therapeutic approach. It improves your exercise outcomes and helps you become a healthier, thinner version of yourself. While some people lack the time or motivation to follow the rigorous guide ...

HAWKESBURY, Ontario, March 18, 2025 (GLOBE NEWSWIRE) -- Des soutiens gouvernementaux sont indispensables face aux nouvelles pertes d’emplois découlant des tarifs douaniers imposés par les États-Unis sur les exportations canadiennes d’acier et d’aluminium. Le Syndicat des Métallos et le Congrès du travail du Canada (CTC) organisent un point de presse à Hawkesbury, dans l’est de l’Ontario, auquel participeront les sections locales des Métallos touchées par les licenciements permanents et temporaires annoncés ...

Avis Budget Group (CAR) shares soared 11.6% in the last trading session to close at $61.95. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 36.4% loss over the past four weeks.The stock has recorded this price rise as the company’s improves on the back of growth in the leisure business, driven by robust international inbound and inter-European cross-border leisure travel.This car rental company is expected to post quarterly loss ...

The auto industry is currently in a state of nervous anticipation, and that's not good for associated companies. One striking case in point is auto rental mainstay Avis Budget Group (CAR -11.41%), whose share price according to data compiled by S&P Global Market Intelligence was down by more than 25% week to date as of early Friday morning.Troubled about tariffsAvis didn't have any negative news of its own to report. Still, investors were rightfully concerned about its vulnerability to current events -- nam ...

Core Insights - Autolus Therapeutics (NASDAQ: AUTL) is a biotech company that has shown significant potential, with previous optimism regarding its clinical development not being fully recognized by the market [1] Group 1: Company Overview - Autolus Therapeutics is involved in the biotech sector, focusing on clinical trials and development of therapies [1] Group 2: Analyst Background - The analysis is conducted by an individual with a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, emphasizing the importance of understanding the science behind investments [1]

Core Viewpoint - Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against Avis Budget Group, Inc. (ABG) and its officers/directors [1] Company Overview - Avis Budget Group, Inc. is a leading global provider of mobility solutions, operating recognized brands such as Avis, Budget, and Zipcar, offering services from car and truck rentals to car sharing [2] Financial Performance - For Q4 2024, ABG reported a loss of $55.66 per share, a significant decline from a profit of $7.10 per share in Q4 2023, attributed to a strategic shift in fleet rotations and a one-time impairment charge [3] - The CEO of ABG will transition to a "Board Advisor" role effective June 30, 2025 [3] Market Reaction - Following the announcement of the financial results, ABG shares fell by 6.82% [4] Management Communication - In the previous quarter's earnings call, management indicated that the fleet buy for 2025 was nearing completion without mentioning potential impairments or write-downs, asserting that they were optimizing the fleet to meet demand [5]

Core Insights - Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against Avis Budget Group, Inc. (ABG) and its officers/directors [1] - ABG is a prominent global provider of mobility solutions, operating brands such as Avis, Budget, and Zipcar, offering services from car rentals to car sharing [2] Financial Performance - For Q4 2024, ABG reported a loss of $55.66 per share, a significant decline from a profit of $7.10 per share in Q4 2023, attributed to a strategic shift in fleet rotations and a one-time impairment charge [3] - The CEO of ABG will transition to a "Board Advisor" role effective June 30, 2025, indicating potential leadership changes within the company [3] Market Reaction - Following the announcement of the financial results, ABG shares experienced a decline of 6.82% [4] Management Communication - In the previous quarter's earnings call, management had indicated that the fleet buy for 2025 was nearing completion without mentioning any potential impairments, suggesting a lack of transparency regarding the fleet's impact on earnings [5]

Core Insights - CARsgen Therapeutics Holdings Limited has received Breakthrough Therapy Designation for its CAR T-cell therapy, satricabtagene autoleucel ("satri-cel"), targeting Claudin18.2-positive advanced gastric/gastroesophageal junction cancer [1][3] - The company plans to submit a New Drug Application (NDA) for satri-cel to the National Medical Products Administration (NMPA) in the first half of 2025 [2] - Satri-cel is positioned to be a first-in-class therapy, with ongoing clinical trials in both China and North America [4] Company Overview - CARsgen is a biopharmaceutical company focused on innovative CAR T-cell therapies for hematologic malignancies and solid tumors, with operations in China and the U.S. [5] - The company has developed a comprehensive CAR T-cell research and development platform, addressing challenges in safety, efficacy, and cost of existing therapies [5] - CARsgen aims to become a global leader in biopharmaceuticals, providing innovative cell therapies for cancer patients worldwide [5]

SHANGHAI, Feb. 27, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR-T therapy targeting CD19/CD20, has administered at the starting dose specified in the clinical protocol to the first patient with systemic lupus erythematosus (SLE) in an investigator-initiated trial (IIT).KJ-C2219 is developed using THANK-u Plus™ pla ...